Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $12.22 and traded as low as $7.00. Arcturus Therapeutics shares last traded at $7.02, with a volume of 484,139 shares.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Guggenheim lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Citigroup cut their price target on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, January 6th. Wells Fargo & Company decreased their price objective on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, October 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Arcturus Therapeutics Price Performance

The company’s 50-day simple moving average is $6.97 and its two-hundred day simple moving average is $12.22. The firm has a market capitalization of $199.44 million, a P/E ratio of -2.85 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%.The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $17.47 million. Analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership grew its position in shares of Arcturus Therapeutics by 1,371.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock valued at $10,177,000 after purchasing an additional 514,652 shares in the last quarter. Millennium Management LLC bought a new position in Arcturus Therapeutics during the first quarter valued at approximately $4,892,000. Bank of America Corp DE grew its holdings in Arcturus Therapeutics by 112.0% during the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after buying an additional 327,626 shares in the last quarter. Diversify Advisory Services LLC increased its stake in Arcturus Therapeutics by 1,136.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 222,500 shares of the biotechnology company’s stock worth $2,895,000 after acquiring an additional 204,500 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Arcturus Therapeutics by 206.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock worth $1,473,000 after acquiring an additional 161,910 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.